TY - JOUR
T1 - Hearing loss prevalence and years lived with disability, 1990-2019
T2 - Findings from the Global Burden of Disease Study 2019
AU - GBD 2019 Hearing Loss Collaborators
AU - Haile, Lydia M.
AU - Kamenov, Kaloyan
AU - Briant, Paul Svitil
AU - Orji, Aislyn U.
AU - Steinmetz, Jaimie D.
AU - Abdoli, Amir
AU - Abdollahi, Mohammad
AU - Abu-Gharbieh, Eman
AU - Afshin, Ashkan
AU - Ahmed, Haroon
AU - Rashid, Tarik Ahmed
AU - Akalu, Yonas
AU - Alahdab, Fares
AU - Alanezi, Fahad Mashhour
AU - Alanzi, Turki M.
AU - Al Hamad, Hanadi
AU - Ali, Liaqat
AU - Alipour, Vahid
AU - Al-Raddadi, Rajaa M.
AU - Amu, Hubert
AU - Arabloo, Jalal
AU - Arab-Zozani, Morteza
AU - Arulappan, Judie
AU - Ashbaugh, Charlie
AU - Atnafu, Desta Debalkie
AU - Babar, Zaheer Ud Din
AU - Baig, Atif Amin
AU - Banik, Palash Chandra
AU - Bärnighausen, Till Winfried
AU - Barrow, Amadou
AU - Bender, Rose G.
AU - Bhagavathula, Akshaya Srikanth
AU - Bhardwaj, Nikha
AU - Bhardwaj, Pankaj
AU - Bibi, Sadia
AU - Bijani, Ali
AU - Burkart, Katrin
AU - Cederroth, Christopher R.
AU - Charan, Jaykaran
AU - Choudhari, Sonali Gajanan
AU - Chu, Dinh Toi
AU - Couto, Rosa A.S.
AU - Dagnew, Amare Belachew
AU - Dagnew, Baye
AU - Dahlawi, Saad M.A.
AU - Dai, Xiaochen
AU - Dandona, Lalit
AU - Dandona, Rakhi
AU - Desalew, Assefa
AU - Dhamnetiya, Deepak
N1 - Funding Information:
LMH reports personal fees from WHO, outside the submitted work. PSB reports personal fees from WHO, outside the submitted work. CRC reports support from the UK National Institute for Health Research (NIHR) Biomedical Research Centre. B-FH was partially supported by China Medical University (CMU109-MF-63), Taichung, Taiwan. SMSI reports grants from National Heart Foundation of Australia and National Health and Medical Research Council (NHMRC); personal fees from WHO; and partial funding by the National Heart Foundation of Australia and NHMRC, outside the submitted work. WM is program analyst in population and development at the UN Population Fund country office in Peru, which does not necessarily endorse this study. JAS reports consultancy fees from Crealta/Horizon, Medisys, Fidia, Two labs, Adept Field Solutions, Clinical Care options, Clearview Healthcare Partners, Putnam Associates, Focus Forward, Navigant Consulting, Spherix, MedIQ, UBM, Trio Health, Medscape, WebMD, Practice Point communications, the National Institutes of Health, and the American College of Rheumatology; payment for lectures including service on Simply Speaking speaker's bureau; stock ownership in TPT Global Tech, Vaxart pharmaceuticals, and Charlotte's Web Holdings. JAS previously owned stock options in Amarin, Viking, and Moderna pharmaceuticals; held placement on the steering committee of OMERACT, an international organisation that develops measures for clinical trials and receives arm's length funding from 12 pharmaceutical companies; serves on the US Food and Drug Administration Arthritis Advisory Committee; is a member of the Veterans Affairs Rheumatology Field Advisory Committee; and is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. ACD reports sponsorship for meeting from GN Foundation; personal fees from GN UK and EarGym; and grants from Siemens/Sivantos UK, during the conduct of the study. ACD has a patent, HearCheck Screener (University of Manchester), with royalties paid through the University of Manchester, and is a member of the WHO Technical Group for World Hearing Repor. All other authors declare no competing interests.
Funding Information:
The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of institutions with which they are affiliated. This manuscript was produced as part of the GBD Collaborator Network and in accordance with the GBD protocol. TWB acknowledges support by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research. AAB acknowledges funding (FRGS/1/2017/SKK06iUNISZA/02/1) under Kementerian Pendidikan Malaysia and Universiti Sultan Zainal Abidin focusing on Streptococcus pneumoniae as one of the main causes of otitis media globally. IL is member of the Sistema Nacional de Investigaci?n, which is supported by the Secretar?a Nacional de Ciencia, Tecnolog?a e Innovaci?n, Panama. JRP acknowledges the support towards research given by Manipal Academy of Higher Education, Manipal, India. AMS acknowledges support from the Egyptian Fulbright Mission Program. MMS-M acknowledges the support of the Ministry of Education, and Science and Technological Development of the Republic of Serbia (Contract 175087). The views expressed herein do not represent those of the NIHR or the UK Department of Health and Social Care.
Funding Information:
The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of institutions with which they are affiliated. This manuscript was produced as part of the GBD Collaborator Network and in accordance with the GBD protocol. TWB acknowledges support by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research. AAB acknowledges funding (FRGS/1/2017/SKK06iUNISZA/02/1) under Kementerian Pendidikan Malaysia and Universiti Sultan Zainal Abidin focusing on Streptococcus pneumoniae as one of the main causes of otitis media globally. IL is member of the Sistema Nacional de Investigación, which is supported by the Secretaría Nacional de Ciencia, Tecnología e Innovación, Panama. JRP acknowledges the support towards research given by Manipal Academy of Higher Education, Manipal, India. AMS acknowledges support from the Egyptian Fulbright Mission Program. MMS-M acknowledges the support of the Ministry of Education, and Science and Technological Development of the Republic of Serbia (Contract 175087). The views expressed herein do not represent those of the NIHR or the UK Department of Health and Social Care.
Publisher Copyright:
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2021/3/13
Y1 - 2021/3/13
N2 - Background: Hearing loss affects access to spoken language, which can affect cognition and development, and can negatively affect social wellbeing. We present updated estimates from the Global Burden of Disease (GBD) study on the prevalence of hearing loss in 2019, as well as the condition's associated disability. Methods: We did systematic reviews of population-representative surveys on hearing loss prevalence from 1990 to 2019. We fitted nested meta-regression models for severity-specific prevalence, accounting for hearing aid coverage, cause, and the presence of tinnitus. We also forecasted the prevalence of hearing loss until 2050. Findings: An estimated 1·57 billion (95% uncertainty interval 1·51–1·64) people globally had hearing loss in 2019, accounting for one in five people (20·3% [19·5–21·1]). Of these, 403·3 million (357·3–449·5) people had hearing loss that was moderate or higher in severity after adjusting for hearing aid use, and 430·4 million (381·7–479·6) without adjustment. The largest number of people with moderate-to-complete hearing loss resided in the Western Pacific region (127·1 million people [112·3–142·6]). Of all people with a hearing impairment, 62·1% (60·2–63·9) were older than 50 years. The Healthcare Access and Quality (HAQ) Index explained 65·8% of the variation in national age-standardised rates of years lived with disability, because countries with a low HAQ Index had higher rates of years lived with disability. By 2050, a projected 2·45 billion (2·35–2·56) people will have hearing loss, a 56·1% (47·3–65·2) increase from 2019, despite stable age-standardised prevalence. Interpretation: As populations age, the number of people with hearing loss will increase. Interventions such as childhood screening, hearing aids, effective management of otitis media and meningitis, and cochlear implants have the potential to ameliorate this burden. Because the burden of moderate-to-complete hearing loss is concentrated in countries with low health-care quality and access, stronger health-care provision mechanisms are needed to reduce the burden of unaddressed hearing loss in these settings. Funding: Bill & Melinda Gates Foundation and WHO.
AB - Background: Hearing loss affects access to spoken language, which can affect cognition and development, and can negatively affect social wellbeing. We present updated estimates from the Global Burden of Disease (GBD) study on the prevalence of hearing loss in 2019, as well as the condition's associated disability. Methods: We did systematic reviews of population-representative surveys on hearing loss prevalence from 1990 to 2019. We fitted nested meta-regression models for severity-specific prevalence, accounting for hearing aid coverage, cause, and the presence of tinnitus. We also forecasted the prevalence of hearing loss until 2050. Findings: An estimated 1·57 billion (95% uncertainty interval 1·51–1·64) people globally had hearing loss in 2019, accounting for one in five people (20·3% [19·5–21·1]). Of these, 403·3 million (357·3–449·5) people had hearing loss that was moderate or higher in severity after adjusting for hearing aid use, and 430·4 million (381·7–479·6) without adjustment. The largest number of people with moderate-to-complete hearing loss resided in the Western Pacific region (127·1 million people [112·3–142·6]). Of all people with a hearing impairment, 62·1% (60·2–63·9) were older than 50 years. The Healthcare Access and Quality (HAQ) Index explained 65·8% of the variation in national age-standardised rates of years lived with disability, because countries with a low HAQ Index had higher rates of years lived with disability. By 2050, a projected 2·45 billion (2·35–2·56) people will have hearing loss, a 56·1% (47·3–65·2) increase from 2019, despite stable age-standardised prevalence. Interpretation: As populations age, the number of people with hearing loss will increase. Interventions such as childhood screening, hearing aids, effective management of otitis media and meningitis, and cochlear implants have the potential to ameliorate this burden. Because the burden of moderate-to-complete hearing loss is concentrated in countries with low health-care quality and access, stronger health-care provision mechanisms are needed to reduce the burden of unaddressed hearing loss in these settings. Funding: Bill & Melinda Gates Foundation and WHO.
UR - http://www.scopus.com/inward/record.url?scp=85102311300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102311300&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(21)00516-X
DO - 10.1016/S0140-6736(21)00516-X
M3 - Article
C2 - 33714390
AN - SCOPUS:85102311300
SN - 0140-6736
VL - 397
SP - 996
EP - 1009
JO - The Lancet
JF - The Lancet
IS - 10278
ER -